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PERSPECTIVE 
Targeting mitoNEET with 
pioglitazone for therapeutic 
neuroprotection after spinal cord 
injury 
There is mounting evidence that targeting mitochondrial 
dysfunction following neurotrauma could be key in devel-
oping effective therapeutic strategies since mitochondria are 
known to play a major role in cellular bioenergetics, function, 
and survival following traumatic spinal cord injury (SCI) 
(Rabchevsky et al., 2011). Our research group is one of the 
pioneers in targeting mitochondrial dysfunction to foster 
functional neuroprotection, having documented that phar-
macological maintenance of mitochondrial function acutely 
results in long-term neuroprotection and improved function-
al recover. We have recently reported that treatment with the 
pleiotropic drug, pioglitazone, maintains acute mitochondrial 
integrity correlated with chronic tissue sparing and functional 
recovery after contusion SCI, but that this was not correlated 
with altered neuroinflammation (Patel et al., 2017). We herein 
propose that the mechanism(s) by which pioglitazone confers 
neuroprotection may not be entirely dependent upon its acti-
vation of peroxisome proliferator activated receptor (PPAR), 
a member of nuclear receptor superfamily that can heterod-
imerize in a ligand-dependent and -independent manner to 
regulate gene expression of multiple molecular processes. A 
class of drugs used to treat type 2 diabetes, called thiazolidine-
diones, can modulate PPAR-y therapeutic effects. Also called 
glitazones, these drugs include pioglitazone, rosiglitazone, 
troglitazone and ciglitazone, which are reported to provide 
their therapeutic effects through varying interactions with 
PPAR-y (Park et al., 2007).  
While it has been hy p othesized that PPAR-y modulation 
of inflammation is the basis for reported therapeutic efficacy 
after neurotrauma, it is our contention that the noted anti-in-
flammatory effects of pioglitazone following neurotrauma 
are indirect and based, in part, on tissue preservation due to 
mitochondrial homeostasis and, consequently, greater func-
tional neuroprotection. Similar to our recent report after SCI 
(Patel et al., 2017), we previously found that following con-
tusion traumatic brain injury (TBI), pioglitazone attenuated 
mitochondria dysfunction and improved both tissue sparing 
and behavioral outcome, but without altering neuroinflam -
mation (Sauerbeck et al., 2011). Accordingly, others used 
PPAR antagonists to show that the neuroprotective effects of 
pioglitazone treatment after TBI were independent of PPAR-y 
activation (Thal et al., 2011). To further support our alterna-
tive hy p othesis, studies have shown that pioglitazone binds 
to mitoNEET, a novel mitochondrial membrane protein, and 
that pioglitazone binding to mitoNEET is able to inhibit its 
[2Fe-2S] cluster transfer upon binding (see Tamir et al., 2015 
and references within). However, the role of such a mecha-
nism in providing therapy after central nervous system (CNS) 
injury is unknown, although it may be related to prevention 
of its dimerization. 
MitoNEET is a protein localized in the brain, liver and 
skeletal muscles of rodents, a finding long after the discovery 
that pioglitazone has a binding affinity for the mitochondrial 
membrane that is mediated through a new m-17 kDa protein, 
later termed mitoNEET (Tamir et al., 2015). At the time of its 
discovery, mitoNEET was proposed to be a pivotal protein 
for mitochondrial metabolism that had the potential of being 
modulated by pioglitazone. Since its initial discovery, the ex-
act role of mitoNEET in the cell remains uncertain. However, 
a handful of groups have studied mitoNEET's protein dy n am-
ics and suggested one possible role is to be a shuttle protein 
for the mitochondria (Tamir et al., 2015). Additionally, in 
mitoNEET knockout mice the mitochondria have decreased 
oxidative capacity, which suggests that it may be pivotal in 
controlling the rate of mitochondrial respiration, notably as 
a redox-sensitive protein that can be reduced by biological 
thiols such as glutathione (GSH), reversing the effect of mi-
toNEET oxidation (Tamir et al., 2015). This may account for 
our demonstration that novel GSH precursors prevent mito-
chondrial dy sfunction and afford neuroprotection following 
traumatic SCI and TBI (Pandya et al., 2014; Patel et al., 2014), 
and we have more recently reported on the identification of 
small molecules that bind to mitoNEET that might be tar-
geted pharmacologically after CNS trauma (Geldenhuys et 
al., 2016; Yonutas et al., 2016). These ligands are built on the 
glitazone backbone by truncating the PP AR binding moiety 
(Tamir et al., 2015), allowing these novel compounds to tar-
get mitoNEET directly without any subsequent direct PP AR 
activation. 
While we have documented that pioglitazone administered  
at 15 minutes or 3 hours after SCI significantly maintains mi- 
tochondrial respiration 24 hours post-injury (Figure 1A), our 
recent findings indicate that pioglitazone is neuroprotective 
following SCI by maintaining mitochondrial homeostasis via 
direct interactions with mitoNEET. Specifically, pioglitazone 
administration to mitoNEET knockout (KO) (-/-) mice does  
not maintain mitochondrial function following SCI (Figure   
1B). Therefore, unlike beneficial effects seen in wild-type  
(WT) mice, pioglitazone treatment was ineffective at improv-  
ing mitochondrial respiration in mitoNEET KO mice. 
Collectively, our data provide a foundation for the novel 
hypothesis that pioglitazone benefits following SCI are de-
pendent upon its interactions with mitoNEET. Accordingly, 
ongoing experiments are directly testing this hypothesis to 
establish, mechanistically, the basis for pioglitazone neuro-
protection with the ultimate goal of using novel specific mi-
toNEET ligands as novel therapeutics for both SCI and TBI, 
as well as a wide range of neurological disease states. 
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Figure I Pioglitazone (Pio) is ineffective at maintaining mitochondrial state III respiration (OCR) in mitoNEET knockout (KO) mice. 
(A) At 24 hours after traumatic spinal cord injury (SCI) (vehicle) in wild-type (WT) mice, there was a significant reduction in OCR (oxidative 
phosphorylation), as well as NADH-linked electron transport system (ETS) (state V-I) capacity. Administration of Pio (10 mg/kg) at 15 minutes or  
3 hours post-injury followed by a booster at 24 hours significantly maintained mitochondrial respiration at 25 hours post-injury (Patel et al., 2017). 
(B) Compared to sham, SCI also resulted in reduced mitochondrial respiration in mitoNEET KO mice. However, unlike WT, similar treatment  
with 10 mg/kg Pio in injured mitoNEET KO mice did not restore mitochondrial respiration at 25 hours post-SCI. Bars represent the mean ± SEM,  
n = 7-10/group (A), 3/group (B). *P < 0.05, vs. sham group; #P < 0.05, vs. vehicle group.  
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